Skip to content

Research guide

Wegovy vs Zepbound: The Head-to-Head Trial and Approved Uses

Wegovy is semaglutide, Zepbound is tirzepatide. The pivotal trials, a real head-to-head study, and what each drug's own FDA label adds the other doesn't.

On this page

Wegovy and Zepbound are the two brand names people actually type into a search bar, more often than the molecule names behind them. Wegovy is semaglutide, approved by the FDA for chronic weight management in 2021. Zepbound is tirzepatide, approved for the same purpose in 2023. Here is what separates them beyond the name on the pen.

The pivotal trials, separately

Neither drug's headline weight-loss number comes from a trial that pitted the two brands against each other. Wegovy's comes from STEP 1: roughly 15% mean weight loss at 68 weeks, versus about 2.4% on placebo1. Zepbound's comes from SURMOUNT-1: up to roughly 21% at the 15 mg dose over 72 weeks2. Those numbers get cited constantly as if they were run under identical conditions — they weren't. Different trials, different populations, different follow-up windows. Treat a straight subtraction of the two headline percentages as suggestive, not proof.

The one real head-to-head that exists

In the 2025 randomized, open-label SURMOUNT-5 trial, 751 adults with obesity without diabetes were assigned to injectable tirzepatide or semaglutide. At 72 weeks, the estimated mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide6. The comparison applies to the injectable regimens studied. Our semaglutide and tirzepatide evidence comparison explains how this differs from the diabetes-dose trial.

A separate 2024 retrospective cohort study in JAMA Internal Medicine examined use in routine care. Researchers matched over 18,000 adults with overweight or obesity who started either drug in routine clinical care and tracked on-treatment weight change3. Tirzepatide patients lost significantly more weight at every checkpoint: 2.4 percentage points more at 3 months, 4.3 more at 6 months, and 6.9 more at 12 months. They were also more likely to hit major thresholds — a hazard ratio of 3.24 for reaching 15% or more weight loss compared with semaglutide patients. Rates of gastrointestinal adverse events were similar between the two groups. This was a real-world EHR-based study, not a randomized trial, so it can't rule out that people prescribed one drug differed from people prescribed the other in ways researchers couldn't fully adjust for — but it is real evidence, not a marketing claim, and it points the same direction as the separate pivotal trials.

What each label carries that the other doesn't

Wegovy's FDA label expanded in March 2024 to include reducing the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight — the SELECT trial indication. That claim is unique to Wegovy; Zepbound's label does not carry it. Zepbound, in turn, is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial — a claim Wegovy's label does not carry. If either condition applies to you, the drug-specific approval is worth knowing before the weight-loss percentage is. The full OSA evidence, including the actual trial numbers, is in Zepbound and sleep apnea; the cardiovascular story is in GLP-1, the heart and the kidneys.

Dosing and how long each stays active

Both are once-weekly subcutaneous injections with a slow titration schedule built to manage GI side effects — see GLP-1 dosage and titration schedules for the full week-by-week numbers. Semaglutide's elimination half-life is approximately one week, so Wegovy stays in circulation for roughly 5 to 7 weeks after the last dose; tirzepatide's half-life is approximately 5–6 days, so Zepbound clears in a comparable but slightly shorter window. Neither difference is large enough to be a deciding factor on its own — see how long GLP-1 drugs stay in your system if the timing matters for surgery, pregnancy planning, or switching.

How to actually decide

On the retrospective evidence, tirzepatide (Zepbound) tends to produce more weight loss for more people. That is a real point in its favor, not a reason to treat semaglutide (Wegovy) as the weaker choice by default — individual response varies, semaglutide has the longer real-world track record and the unique cardiovascular claim, and cost typically favors it in our ranking. If sleep apnea or established cardiovascular disease applies to you, the drug-specific label claim may matter more than either weight-loss number. For the mechanism-level comparison between the molecules themselves, including tolerability, read semaglutide vs tirzepatide; for the diabetes-labeled sibling of Zepbound, see Mounjaro vs Zepbound. Once you know which drug you want, CoreAge Rx carries both on one account, and the semaglutide and tirzepatide rankings rank the field by molecule. The rest of our sourced evidence on these drugs is in the research library.

Frequently asked questions

Does Zepbound work better than Wegovy?

In the randomized SURMOUNT-5 trial in adults with obesity without diabetes, mean weight change at 72 weeks was −20.2% on injectable tirzepatide and −13.7% on injectable semaglutide. That difference describes the study groups and regimens.

Is there a real head-to-head trial between Wegovy and Zepbound?

Yes. SURMOUNT-5 randomized adults with obesity without diabetes to once-weekly injectable tirzepatide or semaglutide and followed them for 72 weeks.

Does Wegovy or Zepbound have an advantage the other doesn't?

Yes, each carries a label claim the other doesn't. Wegovy is FDA-approved to reduce cardiovascular risk in adults with established heart disease and obesity. Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

Which stays in your system longer, Wegovy or Zepbound?

Both clear over a similar multi-week window. Semaglutide's (Wegovy's) half-life is about a week, so it's out of your system in roughly 5 to 7 weeks after the last dose. Tirzepatide's (Zepbound's) half-life is about 5 to 6 days, clearing in a comparable but slightly shorter window.

Sources and further reading

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine. https://pubmed.ncbi.nlm.nih.gov/38976257/
  4. U.S. Food and Drug Administration (2026). Wegovy (semaglutide) injection — Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  5. U.S. Food and Drug Administration (2026). Zepbound (tirzepatide) injection — Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  6. Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40353578/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.